Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
3.07% $61.02
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 807.80 mill |
EPS: | -18.69 |
P/E: | -3.26 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 13.24 mill |
Avg Daily Volume: | 0.183 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.26 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.55x |
Company: PE -3.26 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0133 (-99.98%) $-61.01 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 57.05 - 64.77 ( +/- 6.33%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-12 | Mastrocola Lauren | Sell | 48 | Common Stock |
2024-02-12 | Nemiroff Alex | Sell | 51 | Common Stock |
2024-02-12 | Souza Marcio | Sell | 271 | Common Stock |
2024-01-12 | Kelly Timothy Edwin | Buy | 30 000 | Stock Option (Right to Buy) |
2024-01-12 | Souza Marcio | Buy | 100 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.15 |
Last 99 transactions |
Buy: 3 195 196 | Sell: 875 304 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $61.02 (3.07% ) |
Volume | 1.769 mill |
Avg. Vol. | 0.183 mill |
% of Avg. Vol | 964.00 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $45.25 | N/A | Active |
---|
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.